SCHEMBL5362803

SCHEMBL5362803

COc1c(C(C)C)cc(C=C2C(=O)Nc3ccc(Br)c(C)c32)cc1C(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK4 O00444 2/20 0.47
LRRK2 Q5S007 3/20 0.44
ERBB2 P04626 4/20 0.43
EGFR P00533 3/20 0.43
PDGFRB P09619 2/20 0.43
IGF1R P08069 2/20 0.43
NOX4 Q9NPH5 1/20 0.43
RAF1 P04049 3/20 0.39
AURKA O14965 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
GSK3B P49841 2/20 0.38
PLK1 P53350 1/20 0.38
CHEK1 O14757 1/20 0.37
TTR P02766 1/20 0.36
INSR P06213 1/20 0.36
PSEN1 P49768 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6388353 0.87 LRRK2 (0.49) PLK4LRRK2ERBB2EGFRPDGFRB
SCHEMBL6388348 0.87 LRRK2 (0.49) PLK4LRRK2ERBB2EGFRPDGFRB
SCHEMBL5370263 0.86 ERBB2 (0.44) PLK4LRRK2ERBB2EGFRPDGFRB
SCHEMBL5369299 0.86 EGFR (0.59) PLK4LRRK2ERBB2EGFRPDGFRB
SCHEMBL5358747 0.85 PLK4 (0.60) PLK4LRRK2ERBB2EGFRKDM4E
SCHEMBL7139026 0.83 MEN1 (0.40) PLK4LRRK2ERBB2EGFRPDGFRB
SCHEMBL5366011 0.82 ERBB2 (0.61) PLK4LRRK2ERBB2EGFRIGF1R
SCHEMBL6407240 0.82 RET (0.55) LRRK2ERBB2EGFRPDGFRBIGF1R
SCHEMBL6407238 0.82 RET (0.55) LRRK2ERBB2EGFRPDGFRBIGF1R
SCHEMBL5362776 0.81 ERBB2 (0.67) PLK4LRRK2ERBB2EGFRIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK PLK4 42/4885LRRK2 289/4885ERBB2 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.